IN8BIO

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, provided an update today from the ongoing Phase 1 clinical trial of INB-200, an autologous DeltEx drug resistant immunotherapy (DRI). DeltEx DRI consists of gamma-delta T cells that have been genetically engineered to be chemotherapy resistant, allowing them to be administered concurrently with alkylating chemotherapeutic agents, including temozolomide (TMZ). This clinical trial, conducted in patients newly diagnosed with glioblastoma multiforme (GBM), is the first and most clinically advanced trial to use genetically modified gamma-delta T cells and includes a multi-dose escalation regimen.

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

IN8bio Inc (NASDAQ: INAB) has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia patients undergoing haploidentical hematopoietic stem cell transplant (HSCT).  The three patients with relapsed acute myeloid leukemia (AML) treated to date demonstrate that allogeneic gamma-delta T cell therapy has a manageable toxicity profile with the potential for durable responses in high-risk patients.

IN8bio Stock Jumps After An Update From Leukemia Trial

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) --  IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today provided an update from the ongoing Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical hematopoietic stem cell transplant (HSCT). The three patients with relapsed acute myeloid leukemia (AML) treated to date demonstrate that allogeneic gamma-delta T cell therapy has a manageable toxicity profile with the potential for durable responses in high-risk patients. Haploidentical HSCT patients have high relapse rates of up to 50% at one-year post-treatment. All three of the INB-100 treated patients remain in remission with two patients in remission at 18 and 20 months, respectively. No treatment-related grade 3 or greater adverse events, infusion reactions or dose-limiting toxicities were observed. The trial continues to track these patients and enroll additional patients.

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, today announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer (COO). Dr. Rochlin previously served as Vice President, Operations and Innovation.

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the appointment of Trishna Goswami, M.D. as Chief Medical Officer.

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its proprietary DeltEx platform, today announced a poster presentation of preclinical data demonstrating the potential of its cellular therapies in combination with Poly (ADP-ribose) polymerase (PARPi) and checkpoint inhibitors, which may enhance the recognition and killing of cancer cells by its DeltEx drug resistant immunotherapy (DRI) gamma-delta T cells. Kate Rochlin, Ph.D., Vice President, Operations and Innovation at IN8bio, will present on the potential uses of such therapeutic combinations to drive tumor immunogenicity in the solid tumor setting at the 36th Annual Meeting of the Society for Immunotherapy Conference (SITC).

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors

NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the third quarter ended September 30, 2021. In addition, the Company provided an overview of recent corporate developments.

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific conferences in November.

IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO

Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma

IN8bio's Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present a company overview as well as participate on an Oncology panel at BioFuture 2021. Kate Rochlin, Vice President, Operations and Innovation of IN8bio, will present on the company's gamma delta T-cell programs in Oncology at the Advanced Therapies Congress & Expo 2021.

IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021

GoHealth, Inc.

Shift Technologies

Talkspace

BrightSpire Capital

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Scorching Buy-Rated Stocks Trading Under $10 With Big Upside Potential

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the second quarter ended June 30, 2021. In addition, the Company provided an overview of recent corporate developments.

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, President, Chief Executive Officer and co-founder of IN8bio, will present at the NewYorkBIO Virtual Breakfast Series and the virtual H.C. Wainwright 23rd Annual Global Investment Conference.

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference

The first cohort has completed dosing with IN8bio's donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) observed to date

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies utilizing its DeltEx platform (“IN8bio” or the “Company”), today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $40 million, before underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered by IN8bio. IN8bio's common stock is expected to begin trading on The Nasdaq Global Market on July 30, 2021, under the symbol “INAB.” The offering is expected to close on August 3, 2021, subject to satisfaction of customary closing conditions. In addition, IN8bio has granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

IN8bio Announces Pricing of Initial Public Offering

News for IN8BIO Stock (INAB)